Understanding graft-induced dyskinesia

Regenerative Medicine

Volumn 5, Issue 5, 2010, Pages 787-797

  Lane, E L ^a   Smith, G A ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

6 hydroxydopamine lesioned rat; graft induced dyskinesia; Parkinson's disease; transplantation; ventral mesencephalon

Indexed keywords

AMPHETAMINE; ANTIPARKINSON AGENT; AZATHIOPRINE; CYCLOSPORIN; DOPA; DOPAMINE; LEVODOPA; PLACEBO; PREDNISOLONE; SEROTONIN;

ALLOGRAFT; AUTOTRANSPLANTATION; BRAIN DEPTH STIMULATION; CATECHOLAMINE NERVE CELL; CELL TRANSPLANTATION; CLINICAL TRIAL; DISEASE COURSE; DISEASE MODEL; DOPAMINERGIC NERVE CELL; DYSKINESIA; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; MESENCEPHALON; MOTOR DYSFUNCTION; NONHUMAN; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SEROTONINERGIC NERVE CELL; TREATMENT DURATION;

CELL TRANSPLANTATION; DYSKINESIAS; HUMANS; LEVODOPA; PARKINSON DISEASE;

EID: 77957561738     PISSN: 17460751     EISSN: None     Source Type: Journal    
DOI: 10.2217/rme.10.42     Document Type: Review

References (85)

1. Parkinson J: An Essay On The Shaking Palsy. Sherwood, Neely and Jones, London, UK (1817).
2. Chaudhuri KR, Healy DG, Schapira AH: Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol. 5, 235-245 (2006).
3. Ahlskog JE, Muenter MD: Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov. Disord. 16, 448-458 (2001).
4. Muller T, Russ H: Levodopa, motor fluctuations and dyskinesia in Parkinson's disease. Expert Opin. Pharmacother. 7, 1715-1730 (2006).
5. Cenci MA, Lindgren HS: Advances in understanding L-DOPA-induced dyskinesia. Curr. Opin. Neurobiol. 17, 665-671 (2007).
6. Carta M, Carlsson T, Munoz A, Kirik D, Bjorklund A: Involvement of the serotonin system in L-dopa-induced dyskinesias. Parkinsonism Relat. Disord. 14 (Suppl. 2), S154-S158 (2008).
7. Brundin P, Nilsson OG, Strecker RE et al.: Behavioural effects of human fetal dopamine neurons grafted in a rat model of Parkinson's disease. Exp. Brain Res. 65, 235-240 (1986).
8. Bjorklund A, Dunnett SB, Stenevi U, Lewis ME, Iversen SD: Reinnervation of the denervated striatum by substantia nigra transplants: functional consequences as revealed by pharmacological and sensorimotor testing. Brain Res. 199, 307-333 (1980).
9. Nadaud D, Herman JP, Simon H, Le Moal M: Functional recovery following transplantation of ventral mesencephalic cells in rat subjected to 6-OHDA lesions of the mesolimbic dopaminergic neurons. Brain Res. 304, 137-141 (1984).
10. Backlund EO, Granberg PO, Hamberger B et al.: Transplantation of adrenal medullary tissue to striatum in parkinsonism. First clinical trials. J. Neurosurg. 62, 169-173 (1985). (Pubitemid 15159941)
11. Markham CM, Rand RW, Jacques DB et al.: Transplantation of fetal mesencephalic tissue in Parkinson's patients. Stereotact. Funct. Neurosurg. 62, 134-140 (1994).
12. Peschanski M, Defer G, N'Guyen JP et al.: Bilateral motor improvement and alteration of L-dopa effect in two patients with Parkinson's disease following intrastriatal transplantation of fetal ventral mesencephalon. Brain 117 (Pt 3), 487-499 (1994).
13. Freeman TB, Olanow C W, Hauser RA et al.: Bilateral fetal nigral transplantation into the postcommissural putamen in Parkinson's disease. Ann. Neurol. 38, 379-388 (1995).
14. Defer GL, Geny C, Ricolfi F et al.: Long-term outcome of unilaterally transplanted parkinsonian patients. I. Clinical approach. Brain 119 (Pt 1), 41-50 (1996).
15. Kopyov OV, Jacques DS, Lieberman A, Duma CM, Rogers RL: Outcome following intrastriatal fetal mesencephalic grafts for Parkinson's patients is directly related to the volume of grafted tissue. Exp. Neurol. 146, 536-545 (1997).
16. Kordower JH, Freeman TB, Chen EY et al.: Fetal nigral grafts survive and mediate clinical benefit in a patient with Parkinson's disease. Mov. Disord. 13, 383-393 (1998).
17. Lindvall O: Update on fetal transplantation: the Swedish experience. Mov. Disord. 13 (Suppl. 1), 83-87 (1998).
18. Freed CR, Greene PE, Breeze RE et al.: Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N. Engl. J. Med. 344, 710-719 (2001). ••First full report of graft-induced dyskinesia following transplantation in a double-blind, placebo-controlled study.
19. Olanow CW, Goetz CG, Kordower JH et al.: A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann. Neurol. 54, 403-414 (2003).
20. Greene P, Fahn S, Tsai WY et al.: Severe spontaneous dyskinesias: a disabling complication of embryonic dopaminergic tissue implants in a subset of transplanted patients with advanced Parkinson's disease. Mov. Disord. 14, 904 (1999). • First report of graft-induced dyskinesia in patients after transplantation.
21. Hagell P, Piccini P, Bjorklund A et al.: Dyskinesias following neural transplantation in Parkinson's disease. Nat. Neurosci. 5, 627-628 (2002). (Pubitemid 34742975)
22. Piccini P, Pavese N, Hagell P et al.: Factors affecting the clinical outcome after neural transplantation in Parkinson's disease. Brain 128, 2977-2986 (2005). •• Clinical examination of the factors influencing the success of transplantation in the Lund cohort.
23. Olanow CW, Gracies JM, Goetz CG et al.: Clinical pattern and risk factors for dyskinesias following fetal nigral transplantation in Parkinson's disease: a double blind video-based analysis. Mov. Disord. 24, 336-343 (2009). •• Clinical examination of the factors influencing the success of transplantation in the Tampa-Mount Sinai cohort.
24. Freed C, Breeze R, Fahn S, Eidelberg D: Preoperative response to levodopa in the best predictor of transplant outcome. Ann. Neurol. 55, 896; author reply 896-897 (2004).
25. Cho C, Alterman R, Miravite J, Shils J, Taglati M: Subthalamic DBS for the treatment of 'runaway' dyskinesias after embryonic or fetal tissue transplant. Mov. Disord. 20, 1237 (2005).
26. Herzog J, Pogarell O, Pinsker MO et al.: Deep brain stimulation in Parkinson's disease following fetal nigral transplantation. Mov. Disord. 23, 1293-1296 (2008).
27. Ma Y, Feigin A, Dhawan V et al.: Dyskinesia after fetal cell transplantation for parkinsonism: a PET study. Ann. Neurol. 52, 628-634 (2002).
28. Winkler C, Kirik D, Bjorklund A: Cell transplantation in Parkinson's disease: how can we make it work? Trends Neurosci. 28, 86-92 (2005).
29. Goetz CG, Stebbins GT, Blasucci LM, Grobman MS: Efficacy of a patient-training videotape on motor fluctuations for on-off diaries in Parkinson's disease. Mov. Disord. 12, 1039-1041 (1997).
30. Cenci MA, Hagell P: Dyskinesia and neural grafting in Parkinson's disease. In: Restorative Therapies In Parkinson's Disease. Brundin P, Olanow W (Eds). Kluwer Academic/Plenum Publishers, NY, USA, 184-224 (2006).
31. Langston J W, Ballard P: Parkinsonism induced by 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine (MPTP) : implications for treatment and the pathogenesis of Parkinson's disease. Can. J. Neurol. Sci. 11, 160-165 (1984).
32. Cenci MA, Lee CS, Bjorklund A: L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin-and glutamic acid decarboxylase mRNA. Eur. J. Neurosci. 10, 2694-2706 (1998).
33. Redmond DE, Vinuela A, Kordower JH, Isacson O: Influence of cell preparation and target location on the behavioral recovery after striatal transplantation of fetal dopaminergic neurons in a primate model of Parkinson's disease. Neurobiol. Dis. 29, 103-116 (2008).
34. Lane EL, Winkler C, Brundin P, Cenci MA: The impact of graft size on the development of dyskinesia following intrastriatal grafting of embryonic dopamine neurons in the rat. Neurobiol. Dis. 22, 334-345 (2006).
35. Vinuela A, Hallett PJ, Reske-Nielsen C et al.: Implanted reuptake-deficient or wild-type dopaminergic neurons improve ON L-dopa dyskinesias without OFF-dyskinesias in a rat model of Parkinson's disease. Brain 131, 3361-3379 (2008).
36. Steece-Collier K, Collier TJ, Danielson PD et al.: Embryonic mesencephalic grafts increase levodopa-induced forelimb hyperkinesia in parkinsonian rats. Mov. Disord. 18, 1442-1454 (2003).
37. Maries E, Kordower JH, Chu Y et al.: Focal not widespread grafts induce novel dyskinetic behavior in parkinsonian rats. Neurobiol. Dis. 21, 165-180 (2006).
38. Soderstrom KE, Meredith G, Freeman TB et al.: The synaptic impact of the host immune response in a parkinsonian allograft rat model: influence on graft-derived aberrant behaviors. Neurobiol. Dis. 32, 229-242 (2008).
39. Steece-Collier K, Soderstrom KE, Collier TJ, Sortwell CE, Maries-Lad E: Effect of levodopa priming on dopamine neuron transplant efficacy and induction of abnormal involuntary movements in parkinsonian rats. J. Comp. Neurol. 515, 15-30 (2009).
40. Lane EL, Soulet D, Vercammen L, Cenci MA, Brundin P: Neuroinflammation in the generation of post-transplantation dyskinesia in Parkinson's disease. Neurobiol. Dis. 32, 220-228 (2008).
41. Lane EL, Brundin P, Cenci MA: Amphetamine-induced abnormal movements occur independently of both transplant-and host-derived serotonin innervation following neural grafting in a rat model of Parkinson's disease. Neurobiol. Dis. 35, 42-51 (2009).
42. Lane EL, Vercammen L, Cenci MA, Brundin P: Priming for L-DOPA-induced abnormal involuntary movements increases the severity of amphetamine-induced dyskinesia in grafted rats. Exp. Neurol. 219, 255-258 (2009).
43. Carlsson T, Winkler C, Lundblad M et al.: Graft placement and uneven pattern of reinnervation in the striatum is important for development of graft-induced dyskinesia. Neurobiol. Dis. 21, 657-668 (2006). • First report of amphetamine-induced abnormal involuntary movements in the rodent model.
44. Carlsson T, Carta M, Winkler C, Bjorklund A, Kirik D: Serotonin neuron transplants exacerbate L-DOPA-induced dyskinesias in a rat model of Parkinson's disease. J. Neurosci. 27, 8011-8022 (2007).
45. Cenci MA, Lundblad M: Ratings of L-DOPA-induced dyskinesia in the unilateral 6-OHDA lesion model of Parkinson's disease in rats and mice. Curr. Protoc. Neurosci. Chapter 9, Unit 9, 25 (2007).
46. Winkler C, Kirik D, Bjorklund A, Cenci MA: L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of Parkinson's disease: relation to motor and cellular parameters of nigrostriatal function. Neurobiol. Dis. 10, 165-186 (2002).
47. Lee CS, Cenci MA, Schulzer M, Bjorklund A: Embryonic ventral mesencephalic grafts improve levodopa-induced dyskinesia in a rat model of Parkinson's disease. Brain 123 (Pt 7), 1365-1379 (2000).
48. Gaudin DP, Rioux L, Bedard PJ: Fetal dopamine neuron transplants prevent behavioral supersensitivity induced by repeated administration of L-dopa in the rat. Brain Res. 506, 166-168 (1990).
49. Carlsson T, Carta M, Munoz A et al.: Impact of grafted serotonin and dopamine neurons on development of L-DOPA-induced dyskinesias in parkinsonian rats is determined by the extent of dopamine neuron degeneration. Brain 132, 319-335 (2009).
50. Kuan WL, Lin R, Tyers P, Barker RA: The importance of A9 dopaminergic neurons in mediating the functional benefits of fetal ventral mesencephalon transplants and levodopa-induced dyskinesias. Neurobiol. Dis. 25, 594-608 (2007).
51. Jacques DB, Kopyov OV, Eagle KS, Carter T, Lieberman A: Outcomes and complications of fetal tissue transplantation in Parkinson's disease. Stereotact. Funct. Neurosurg. 72, 219-224 (1999).
52. Ungerstedt U: Striatal dopamine release after amphetamine or nerve degeneration revealed by rotational behaviour. Acta Physiol. Scand. Suppl. 367, 49-68 (1971).
53. Ungerstedt U, Arbuthnott GW: Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system. Brain Res. 24, 485-493 (1970).
54. Herman JP, Rouge-Pont F, Le Moal M, Abrous DN: Mechanisms of amphetamineinduced rotation in rats with unilateral intrastriatal grafts of embryonic dopaminergic neurons: a pharmacological and biochemical analysis. Neuroscience 53, 1083-1095 (1993).
55. Torres EM, Dunnett SB: Amphetamine induced rotation in the assessment of lesions and grafts in the unilateral rat model of Parkinson's disease. Eur. Neuropsychopharmacol. 17, 206-214 (2007).
56. Kelley AE, Lang CG, Gauthier AM: Induction of oral stereotypy following amphetamine microinjection into a discrete subregion of the striatum. Psychopharmacology 95, 556-559 (1988).
57. Brown LL, Sharp FR: Metabolic mapping of rat striatum: somatotopic organization of sensorimotor activity. Brain Res. 686, 207-222 (1995).
58. Brown LL: Somatotopic organization in rat striatum: evidence for a combinational map. Proc. Natl Acad. Sci. USA 89, 7403-7407 (1992).
59. Munoz A, Carlsson T, Tronci E et al.: Serotonin neuron-dependent and-independent reduction of dyskinesia by 5-HT1A and 5-HT1B receptor agonists in the rat Parkinson model. Exp. Neurol. 219, 298-307 (2009).
60. Carta M, Carlsson T, Munoz A, Kirik D, Bjorklund A: Serotonin-dopamine interaction in the induction and maintenance of L-DOPA-induced dyskinesias. Prog. Brain Res. 172, 465-478 (2008).
61. Mendez I, Vinuela A, Astradsson A et al.: Dopamine neurons implanted into people with Parkinson's disease survive without pathology for 14 years. Nat. Med. 14, 507-509 (2008).
62. Carlsson T, Carta M, Munoz A et al.: Impact of grafted serotonin and dopamine neurons on development of L-DOPA-induced dyskinesias in parkinsonian rats is determined by the extent of dopamine neuron degeneration. Brain 132, 319-335 (2008).
63. Carta M, Carlsson T, Kirik D, Bjorklund A: Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. Brain 130, 1819-1833 (2007).
64. Henry B, Duty S, Fox SH, Crossman AR, Brotchie JM: Increased striatal preproenkephalin B expression is associated with dyskinesia in Parkinson's disease. Exp. Neurol. 183, 458-468 (2003).
65. Picconi B, Centonze D, Hakansson K et al.: Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia. Nat. Neurosci. 6, 501-506 (2003).
66. Cenci MA, Tranberg A, Andersson M, Hilbertson A: Changes in the regional and compartmental distribution of FosB-and JunB-like immunoreactivity induced in the dopamine-denervated rat striatum by acute or chronic L-dopa treatment. Neuroscience 94, 515-527 (1999).
67. Blunt SB, Jenner P, Marsden CD: Autoradiographic study of striatal D1 and D2 dopamine receptors in 6-OHDA-lesioned rats receiving fetal ventral mesencephalic grafts and chronic treatment with L-dopa and carbidopa. Brain Res. 582, 299-311 (1992).
68. Andersson M, Hilbertson A, Cenci MA: Striatal fosB expression is causally linked with L-DOPA-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson's disease. Neurobiol. Dis. 6, 461-474 (1999).
69. Cenci MA, Campbell K, Bjorklund A: Neuropeptide messenger RNA expression in the 6-hydroxydopamine-lesioned rat striatum reinnervated by fetal dopaminergic transplants: differential effects of the grafts on preproenkephalin, preprotachykinin and prodynorphin messenger RNA levels. Neuroscience 57, 275-296 (1993).
70. Roy E, Cote PY, Gregoire L, Parent A, Bedard PJ: Mesencephalic grafts partially restore normal nigral dynorphin levels in 6-hydroxydopamine-lesioned rats treated chronically with L-dihydroxyphenylalanine. Neuroscience 66, 413-425 (1995).
71. A receptor α-1 and α-2 subunits and metabotropic glutamate receptor 5 in the basal ganglia of the rats with unilateral 6-hydroxydopamine lesion and embryonic mesencephalic grafts. Exp. Neurol. 168, 231-241 (2001).
72. Rodriguez-Pallares J, Caruncho HJ, Munoz A, Guerra MJ, Labandeira-Garcia JL: GABAA receptor subunit expression in intrastriatal ventral mesencephalic transplants. Exp. Brain Res. 135, 331-340 (2000).
73. Chritin M, Savasta M, Mennicken F et al.: Intrastriatal dopamine-rich implants reverse the increase of dopamine D2 receptor mRNA levels caused by lesion of the nigrostriatal pathway: a quantitative in situ hybridization study. Eur. J. Neurosci. 4, 663-672 (1992).
74. Abrous DN, Torres EM, Annett LE, Reading PJ, Dunnett SB: Intrastriatal dopamine-rich grafts induce a hyperexpression of Fos protein when challenged with amphetamine. Exp. Brain Res. 91, 181-190 (1992).
75. Cenci MA, Bjorklund A: Transection of corticostriatal afferents abolishes the hyperexpression of Fos and counteracts the development of rotational overcompensation induced by intrastriatal dopamine-rich grafts when challenged with amphetamine. Brain Res. 665, 167-174 (1994).
76. Brodsky MA, Hogarth P, Nutt JG: OFF-off rebound dyskinesia in subthalamic nucleus deep brain stimulation of Parkinson's disease. Mov. Disord. 21, 1487-1490 (2006).
77. Merello M, Perez-Lloret S, Antico J, Obeso JA: Dyskinesias induced by subthalamotomy in Parkinson's disease are unresponsive to amantadine. J. Neurol. Neurosurg. Psychiatry 77, 172-174 (2006).
78. Schupbach WM, Chastan N, Welter ML et al.: Stimulation of the subthalamic nucleus in Parkinson's disease: a 5 year follow up. J. Neurol. Neurosurg. Psychiatry 76, 1640-1644 (2005).
79. Thobois S, Mertens P, Guenot M et al.: Subthalamic nucleus stimulation in Parkinson's disease: clinical evaluation of 18 patients. J. Neurol 249, 529-534 (2002). (Pubitemid 34507824)
80. Hagell P, Brundin P: Cell survival and clinical outcome following intrastriatal transplantation in Parkinson disease. J. Neuropathol. Exp. Neurol. 60, 741-752 (2001).
81. Holden C: Neuroscience. Fetal cells again? Science 326, 358-359 (2009).
82. Takahashi K, Tanabe K, Ohnuki M et al.: Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131, 861-872 (2007). • First report of human induced pluripotent stem cells.
83. Andersson E, Tryggvason U, Deng Q et al.: Identification of intrinsic determinants of midbrain dopamine neurons. Cell 124, 393-405 (2006).
84. Li JY, Christophersen NS, Hall V, Soulet D, Brundin P: Critical issues of clinical human embryonic stem cell therapy for brain repair. Trends Neurosci. 31, 146-153 (2008).
85. Kopyov OV, Jacques D, Lieberman A, Duma CM, Rogers RL: Clinical study of fetal mesencephalic intracerebral transplants for the treatment of Parkinson's disease. Cell Transplant 5, 327-337 (1996).